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Type1diabetes(T1D)isachronicautoimmunediseaseandcharacterizedbyabsoluteinsulindeﬁciency.β-cellreplacementbyislet
cell transplantation has been established as a feasible treatment option for T1D. The two main obstacles after islet transplantation
are alloreactive T-cell-mediated graft rejection and recurrence of autoimmune diabetes mellitus in recipients. T cells play a central
role in determining the outcome of both autoimmune responses and allograft survival. B7-H4, a newly identiﬁed B7 homolog,
plays a key role in maintaining T-cell homeostasis by reducing T-cell proliferation and cytokine production. The relationship
between B7-H4 and allograft survival/autoimmunity has been investigated recently in both islet transplantation and the nonobese
diabetic (NOD) mouse models. B7-H4 protects allograft survival and generates donor-speciﬁc tolerance. It also prevents the
development of autoimmune diabetes. More importantly, B7-H4 plays an indispensable role in alloimmunity in the absence of
the classic CD28/CTLA-4:B7 pathway, suggesting a synergistic/additive eﬀect with other agents such as CTLA-4 on inhibition of
unwanted immune responses.
1.Introduction
Type 1 diabetes (T1D) is fatal unless treated with insulin.
Injection of insulin prevents the hyperglycemic compli-
cations of T1D, including ketoacidosis and coma. How-
ever, exogenous administration of excessive or inadequate
amounts of insulin often results in hypo- and hyperglycemia,
respectively [1–3]. Combination of intensive glycemic mon-
itoring and best medical therapy provides better control of
insulin level and reduces the microvascular and macrovascu-
lar complications of diabetes, but it also increases the risk of
severe hypoglycemia [1–3]. In selected patients, islet trans-
plantation is a reasonable therapeutic option. Restoration of
β-cell mass by whole-pancreas or islet cell transplantation
provides physiologically regulated insulin as well as other
hormones, such as glucagon to avoid life-threatening unreg-
ulated glucose levels [4–6]. Whole-pancreas transplantation
is a major surgical procedure and is usually performed in
conjunction with a kidney transplant, either simultaneous
pancreas-kidney transplant (SPK) or pancreas-after-kidney
transplant (PAK), for patients with end-stage renal disease.
By contrast, islet cell transplantation is a less invasive and
relatively simple procedure. Isolated islets are infused into
the liver through the portal vein, guided by ﬂuoroscopic
cannulation. The one-year success rate is comparable for
both types of transplantations. Signiﬁcant progress has been
made in islet transplantation, especially the establishment
of the “Edmonton protocol” in 2000 [7]. This success of
t h i sp r o t o c o li sb a s e do np r o v i s i o no fb o t hs u ﬃcient islet-
cell mass and a steroid-free immunosuppressive regimen.
However, the subsequent followups conducted worldwide in
several centers show a constant decline in graft function [8].
Despite this, the majority of recipients beneﬁt from reduced
overall insulin requirements; improved C-peptide secretion
and HbA1C levels; decreased development of microvascular
complications; and fewer complications related to episodes2 Journal of Transplantation
of hypoglycemia after 5-year followup [9]. Therefore, islet
transplantation is superior to best medical therapy in
terms of better control of metabolism and prevention of
devastating hypoglycemia over long periods.
Oneofthetwomajorchallengesinislettransplantationis
the limited supply of donor islets. The strategies for expand-
ing donor islet supply include the construction of insulin-
producing cells de novo. This can be achieved through four
diﬀerent ways: (1) from transdiﬀerentiation of other types
of cells, such as hepatic cells; (2) from diﬀerentiation of
pancreatic progenitor cells, such as acinar or ductal cells;
(3) from diﬀerentiation of pluripotent stem cells, such as
embryonic stem cells; and (4) from expansion of existing β
cells. There are some excellent reviews on this ﬁeld, and we
will not address this issue in detail [10, 11].
The other central barrier for islet transplant success is
graft failure, or so- called rejection. The current glucocor-
ticoid-free immunosuppressive regimen for islet transplan-
tation includes tacrolimus (FK506) and either sirolimus
(rapamycin) or mycophenolate mofetil (MMF). Although
these immunosuppressive drugs control acute rejection
and enhance islet allograft survival, lack of long-term
eﬃcacy/insulin independence and immunosuppressant-as-
sociated side eﬀects (including risks of cancer, infection,
nephrotoxicity, cardiovascular-related diseases, and even
direct islet toxicity) hamper this great application. The ex-
isting data reveal that current immunosuppressive drugs
induce cytotoxicity to islets and reduce β-cell function. The
function of human islets is impaired by chronic exposure to
FK506 or MMF [12]. FK506, but not MMF, damages human
islet graft function in diabetic NOD.SCID mice [12]. All
three drugs (FK506, MMF, and rapamycin) increase apop-
tosis in islets [12]. Therefore, new strategies are needed to
avoidgeneralizedsuppressionofimmunityanditsassociated
cytotoxicity without alteration of β-cell function. All types of
immunosuppressivedrugsarepresumedtohavesomedegree
of nonspeciﬁc toxicity. In this regard, islet graft function
should be better maintained in the absence of long-term
ongoing immunosuppression. Ideally, a recipient’s immune
system would not reject an islet graft, while continuing to
respond to all other foreign antigens normally. Therefore, an
ultimate goal in transplantation is to induce antigen-speciﬁc
tolerance.
2. Mechanisms of Rejection of
TransplantedGrafts
Rejection is a normal adaptive immune reaction to foreign
antigens. The discovery of the major histocompatibility
complex (MHC) by Jean Dausset in 1958 established human
leukocyte antigen (HLA) as a transplant antigen. Transplan-
tationrejectionoccursbetweenindividualswithmismatched
HLAhaplotypes.Thedegreeofrejectionisdeterminedbythe
level of mismatch in the MHC haplotypes. The more closely
MHC haplotypes are matched between donor and host, the
greater degree of acceptance is observed [13, 14]. In this
regard,MHCmoleculesplayaprimaryroleingraftrejection.
Rejection of donor grafts is the result of humoral and cell-
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Figure 1:Mechanismofgraftrejection.AllogeneicTcellsrecognize
antigen through either a direct or an indirect pathway. In the direct
pathway, T cells recognize intact allogeneic antigen on the surface
of donor-derived APCs. This pathway is thought to predominate
in acute rejection. In the indirect pathway, recipient APCs process
donor-derived alloantigen into peptides and then present them to
recipient T cells. This pathway is thought to dominate chronic
rejection. The activation of T cells through either pathway results
in killing the donor graft.
mediated reactions to major MHC antigens, known as HLA
in humans, H2 in mice, and RT1 in rats [13]. Recognition
of foreign antigens presented on MHC molecules by T-cell
receptors (TCR) initiates T-cell-mediated immune responses
that result in the destruction of transplanted grafts.
T cells play a central role in allograft rejection. Direct
evidencefromadoptivetransferexperimentsshowsthatallo-
graft immunity is conferred after adoptive transfer of lym-
phocytes,butnotofserum[15,16].Inconcordancewiththis
function, depletion of T cells by injection of antibody results
in acceptance of mouse islet allografts [17, 18], suggesting
thatTcellsdeterminethefateoftransplantation.Subsequent
experiments revealed that CD4+ but not CD8+ subsets are
necessary for the rejection of islet allografts [19].
T cells recognize alloantigens through two distinct path-
ways.Analloantigencanbepresentedoneitherdonor(direct
pathway) or recipient (indirect pathway) MHC molecules
(Figure 1). In either pathway, interaction of CD4+ Tc e l l s
with an alloantigen results in activation and production of
cytokines such as IFN-γ and interleukin- (IL-) 2 that
promote diﬀerentiation and proliferation of cytotoxic CD8+
T cells, macrophages, and B cells. These alloreactive cells
can lyse transplanted grafts or produce cytokines that induce
necrosis of donor tissues (Figure 1).
CD4+ cells, also called helper T cells (Th), play a
dominant role in initiating graft rejection [14, 16]. CD4+
Th cells can diﬀerentiate into one of 4 subtypes. Tran-
scription factors T-bet, GATA-3, forkhead box P3 (FoxP3),
and the retinoic acid receptor-related orphan receptor γ
(RORγt) direct diﬀerentiation of Th1, Th2, Treg, and Th17,Journal of Transplantation 3
respectively. Once diﬀerentiated, each lineage secretes a
speciﬁc cytokine proﬁle. For example, Th1 and Th2 subsets
secrete interferon γ (IFN-γ) and IL-4/IL-10, respectively
[14]. The Th1, Th2, Treg, and Th17 subsets cooperate
and inﬂuence the outcome of transplanted grafts. The Th1
cytokine proﬁle was previously thought to be associated with
allograft damage and rejection, while the Th2 proﬁle favors
the acquisition of protection and tolerance [20]. However,
this simpliﬁed Th1/Th2 paradigm may not be suﬃcient
to explain redundant eﬀects of cytokine networks on the
outcome of transplantation in vivo.
The newly characterized regulatory T-cell subset, Tregs,
plays an anti-inﬂammatory role and maintains tolerance to
self-antigens. Tregs (CD4+ CD25+) suppress proliferation of
CD4+ CD25− T cells, CD8+ T cells, dendritic cells, B cells,
macrophages, mast cells, osteoblasts, NK, and NKT cells in
an antigen-non-speciﬁc manner [21]. Tregs play an impor-
tant role in preventing transplant rejection and generating
tolerance [22].
3. Tregs and Transplantation
Treg-mediated tolerance induction has been well established
as a nondeletional strategy to modulate alloreactive T-cell
responses. The role of Tregs in maintaining self-tolerance
wasdescribedbySakaguchi’sgroup,whichshowedthatTregs
from the thymus protect the host from autoimmune diseases
[23].
Tregs can be categorized into two main types (naturally
occurring Tregs, nTregs, and inducible Tregs, iTregs) based
on their origins, mechanisms, and modes of action [24].
They are both called regulatory T cells because they have
similarities in terms of phenotype and function. First, both
express Foxp3 and suppress the proliferation of eﬀector cells.
Secondly,Tregswillbeabsentfromthethymusortheperiph-
ery, if proximal TCR signaling is disrupted, either through
genetic manipulation or the use of calcineurin inhibitors.
Thirdly, the development of both types of Tregs is dependent
on cytokines such as IL-2. The two subsets of Tregs can
be diﬀerentiated by their distinct suppressive mechanisms
and other characteristics. nTregs develop in the thymus and
constitute approximately 5–10% of peripheral CD4+ T cells.
CD4+CD25+ T r e g ss u p p r e s se ﬀector T-cell proliferation in
vitrothrough a cell contact-dependent mechanism, and their
function is cytokine-independent [24]. A role for nTregs in
the development of transplantation tolerance was ﬁrst indi-
cated by their ability to suppress mouse GVHD following
adoptive transfer [25].
The second population of Treg subsets (iTregs) is dis-
tinct from nTregs and arises during immune responses in
the periphery. iTregs suppress immune responses through
secretion of immunosuppressive cytokines. Th3 and Tr1 cells
induce suppression through secretion of TGF-β and IL-10,
respectively, [24]. Tr1 wasﬁrst identiﬁed by Groux et al. [26].
Na¨ ıve T cells from ovalbumin (OVA) TCR-transgenic mice
stimulated with OVA and IL-10 suppress antigen-speciﬁc
activation in vitro and prevent the development of colitis
in vivo [26]. Moreover, the supernatant from Tr1 strongly
suppresses alloantigen-speciﬁc T-cell proliferation [27]. Tr1
cells tend to migrate toward the site of inﬂammation.
Tregs can be detected in the extralymphoid sites. It shows
that CD4+CD25+ Tregs are overexpressed within tolerated
allograft [28]. Th3 was originally described in oral tolerance
in mice induced by myelin basic protein (MBP) [29]. Th3
suppressive cells may be converted from nonregulatory cells
in the presence of TGF-β [30]. The existence of suppressive
cells of nonthymus origin was conﬁrmed by the demon-
stration of CD4+CD25+ conversion from CD25− precursors
in thymectomized mice, and that these non-thymus-derived
Tregs can suppress skin allograft rejection [31].
4. Costimulation Blockade inTransplantation
T cells are the principal mediator of alloreactive reactions,
and their full activation requires 2 signals. The ﬁrst is pro-
vided by the interaction of antigen-speciﬁc TCRs and their
cognate alloantigens presented on MHCs. The second signal
is antigen nonspeciﬁc. It can be provided in trans by APCs
and requires cell-cell contact [32]. Signal 1 alone results
in no response. Signals 1 plus 2 lead to either activation
or inhibition of the T-cell response, depending on which
cosignal pathway dominates. In the presence of positive
signals, such as CD28, T cells become activated upon
stimulation with foreign antigen. On the contrary, activated
T-cell proliferation is terminated with negative coinhibitory
signals, such as CTLA-4 [33]. The requirement of two sep-
arate signals for full activation of the intracellular signalling
cascade, IL-2 transcription, T-cell proliferation, and eﬀector
function suggests a critical role of cosignalling pathways in
determining the fate of transplantation (Figure 2). Much
attention has been focused on using agents which are either
coinhibitory with negative-signal molecules, or antagonistic
to positive-signal molecules, to control allograft rejection.
Thediscoveryoftherequirementofbothrecognitionsig-
nal (signal 1) and veriﬁcation signal (signal 2) for eﬀective T-
cell activation has elucidated potential targets for immuno-
suppression that are highly T-cell speciﬁc. In particular, the
need for additional cosignalling to avoid anergy or apoptosis
has generated the strategy for tolerance induction using
costimulation blockade. In fact, T-cell clones cultured with
antigen and MHC alone lead to unresponsiveness [34]; in
otherwords,Tcellswillundergoanergyorapoptosiswithout
signal 2. This observation suggests the attractive prospect
that allografts could become tolerated if signal 2 is blocked.
Althoughdiversestrategieshavebeeninvestigatedtoenhance
g r a f ts u r v i v a li nt e r m so fi m p r o v e de ﬃcacy and reduced
toxicity, diﬀerent degrees of side eﬀects are unavoidable.
Therefore, tolerance induction or withdrawal of long-term
usage of immunosuppressants is preferred. Theoretically, it
may be achieved by using costimulation blockade.
5. B7-H4 Coinhibitory Pathway
B7-H4 (B7x or B7S) was identiﬁed by three independent
groups using expressed sequence tags (EST) with homology
to the B7 family [35–37]. The genes for human and mouse4 Journal of Transplantation
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Figure 2: The outcome of transplantation is determined by
cosignalling. Full T-cell activation requires two signals. The ﬁrst
is antigen-speciﬁc recognition of TCR and alloantigen presented
on MHC. The second is costimulation which can be positive or
negative. In the presence of positive cosignalling (such as with
CD28),T-cellproliferationoccurs.Theseactivated Tcellsattackthe
donor graft and results in graft rejection. One the other hand, the
activated T-cell response is terminated in the presence of negative
co-signalling (such as with CTLA-4) which protects the graft from
destruction.
B7-H4 are located on chromosomes 1 and 3, respectively.
Genomic DNA of B7-H4 consists of 6 exons and 5 introns,
andmatureproteinisencodedbyan849-bpregionspanning
exons III, IV, and part of V. In both genes, exons I and II
form a signal peptide, and V encodes transmembrane and
intracellular regions.
The extracellular region of B7-H4 contains one Ig V
and one Ig C domain. Within the extracellular domain,
mouseB7-H4shares90%and99%aminoacid(aa)sequence
identity with human and rat B7-H4, respectively, suggesting
a conserved identity among species. Although it shares only
21–29% aa sequence identity with B7.1, B7.2, B7-H1, B7-
H2, B7-H3, and PD-L2 [35], B7-H4 exhibits a similar overall
structure with other members in the B7 family.
B7-H4 mRNA is ubiquitously expressed in both lym-
phoid and nonlymphoid tissues, including placenta, kidney,
liver, lung, ovary, testis, and spleen, suggesting that it plays
a potential role in peripheral tissues [35–37]. The mature
protein is a 50- to -80-kDa glycosylated molecule with a 28-
kDa protein core, and its expression appears to be restricted,
suggesting posttranscriptional/translational regulation. B7-
H4 expression is induced on mitogen- or LPS-activated B
cells, T cells, dendritic cells, monocytes, and macrophages
[35–37].
The Ig V region is responsible for the binding with the
counter-receptor. In B7.1 and B7.2, the V region contains a
c o n s e r v e ds t r a n do fA  GFCC C for CTLA-4/CD28 binding.
B7-H4 contains no such conserved face. In fact, B7-H4 binds
toareceptoronactivatedTcellsbutnottoCTLA-4,ICOS,or
PD-1,accordingtoFACSanalysisofaB7-H4-transfected293
cell line [35–37]. B7-H4 is expressed on wild type (WT) but
not on B- and T-lymphocyte- attenuator- (BTLA-) deﬁcient
cells, suggesting a possible role of BTLA as a B7-H4 receptor
[37]. However, recent studies have indicated that BTLA does
not bind to B7-H4 directly, and that herpes virus entry
mediator(HVEM)maybetheuniqueBTLAligand[38].The
receptor for B7-H4 is still unknown.
The primary function of B7-H4 appears to downregulate
the T-cell response. Several lines of evidence from both in
vitro and in vivo data support this notion. B7-H4 inhibits
normalmouseandhumanTCR-inducedT-cellproliferation,
cytokine production, and cytotoxicity in vitro [35–37].
Similarly,theproliferationofTcellsandthesecretionofIFN-
γ activated by autoantigens (insulin, GAD, and IA-2) from
human T1D patients were suppressed in the presence of B7-
H4. In addition, ectopic expression of B7-H4 in human β
cells also protects these cells from cytotoxicity induced by β-
cell antigen-speciﬁc T-cell clones derived from T1D patients
[39]. The negative eﬀects of B7-H4 on T cells are also con-
ﬁrmedinseveralinvivosystems.AdministrationofB7-H4.Ig
impairs CTL activity in a mouse graft-versus-host disease
(GVHD) model [35]. In concordance with this inhibitory
eﬀect, administration of monoclonal antibody that blocks
endogenous B7-H4 expression increases T-cell proliferation
and IL-2 production [35]. Similarly, the injection of a block-
ing mAb against B7-H4 promotes T-cell responses and exac-
erbates experimental autoimmune encephalomyelitis (EAE)
[36]. Collectively, these results suggest that B7-H4 is a novel
negative regulator in the B7 family.
It is not clearly understood how B7-H4 aﬀects the im-
mune responses. Studies into the mechanisms by which
B7-H4 regulates T-cell immunity show that the suppressive
activity of APCs is associated with expression of B7-H4 in
vitro [40]. B7-H4 expression on APCs is triggered by Tregs
through production of IL-10. Blockade of B7-H4 reduces
the suppressive activity mediated by Treg conditioned APCs.
In addition, Tregs exhibit suppressive activity by stimulating
B7-H4 expression through IL-10. Furthermore, the high
expressionlevelofB7-H4invariouscancercellssuggeststhat
it may help those tumors escape immune surveillance [41].
Primary ovarian tumour cells express intracellular B7-H4,
whereas only a fraction of tumour macrophages express sur-
face B7-H4. B7-H4+ tumour macrophages, but not primary
ovarian tumour cells, suppress tumour-associated antigen-
speciﬁc T-cell immunity. IL-6 and IL-10 are highly expressed
in the tumour environment, and they trigger macrophage
B7-H4expression[42].Collectively,theseresultssuggestthat
a collaborative interaction between B7-H4 and Tregs may
downregulate T-cell immunity.
B7-H4 deﬁcient mice display normal responses to several
types of airway inﬂammation, and they show augmented
Th1 responses, suggesting a preferential regulation on Th1
subsets [43]. Interestingly, a subsequent study revealed that
B7-H4 suppresses neutrophil-mediated immune responses,
indicating its role in innate immunity [44].Journal of Transplantation 5
6. B7-H4 andTransplantation
As described earlier, B7-H4 inhibits alloreactive CTL activity
in mouse GVHD and extends the survival of mice with
GVHD [35]. The role of B7-H4 in islet transplantation was
ﬁrst investigated by our group [45]. Local expression of B7-
H4 by a recombinant adenovirus (Ad-B7-H4) promotes islet
allograft survival in a fully MHC-mismatched mouse model
(fromBALB/ctoC56BL/6)[45].Thisresulthassubsequently
been conﬁrmed by Yuan’s group, using administration of a
B7-H4-transfected NIT cell line into diabetic C57BL/6 mice
[46]. We showed that survival is associated with reduced
CD8+ T cells, preserved β-cell function, and upregulation
of Foxp3+ in the allograft. Yuan’s group showed a reduced
amount of IFN-γ and increased Tregs in the spleen of
B7-H4-treated recipients. Moreover, we used a secondary
transplantation model to demonstrate that B7-H4 not only
promotes allograft survival but also induces donor-speciﬁc
tolerance [45, 47].
Alloreactive responses can be modulated through either
deletional or nondeletional mechanisms. B7-H4 controls
alloreactive responses through downregulating cytotoxic
CD8+ subsetsintheearlystage,suggestingadeletionalmech-
anism in tolerance induction [45]. Furthermore, transcrip-
tionofIFN-γ andgranzymeBweresigniﬁcantlydecreasedin
Ad-B7-H4—treated allografts, suggesting that B7-H4 pref-
erentially inhibits Th1 and CTL locally [47]. The inhibition
of Th1 response by B7-H4 is also demonstrated in B7-
H4-deﬁcient mice which exhibit augmented expression level
of both IFN-γ and T-bet in response to Leishmania major
infection [43]. Whether a reduced amount of CD8+ is
associated with Th1-related cytokines, or that low levels of
IFN-γ results in a reduced CD8 population has not been
investigated. This ﬁnding demonstrates that functional allo-
graft is preserved by B7-H4-mediated negative co-signalling
which limits both helper CD4+ cells towards Th1 formation
and cytotoxic CD8+ cell towards killing donor tissues.
Apart from deletion-mediated tolerance induction, sup-
pression can also be considered a nondeletional mechanism
to modulate alloreactive T-cell responses. In the long term,
B7-H4 preferentially upregulates the number of Foxp3 in the
allograft and Tregs in the periphery, suggesting the involve-
ment of a suppressive mechanism for allograft survival [45,
47]. The outcome of the alloreactive immune response is
determined by the balance of eﬀector and regulatory T cells
in the process of priming na¨ ıve CD4+ T cells in response to
alloantigen stimulation. The development of Th1/Th2 eﬀec-
tors often dominates alloreactive T-cell responses, whereas
theconversionofFoxp3+ fromna¨ ıveoreﬀectorTcellsoccurs
only in the presence of speciﬁc stimuli. Studies into the
relationship between helper and regulatory T-cell subsets
reveal that the development of Foxp3+ in the periphery is
profoundly inhibited by Th1/Th2 activities [48]. Cytokines
for Th1/Th2 polarization, such as IFN-γ, IL-12, and IL-4,
inhibit Treg diﬀerentiation from na¨ ıve cells induced by TGF-
β1, whereas blocking of IFN-γ and/or IL-4 could promote
Foxp3+ Treg diﬀerentiation both in vitro and in vivo [48].
Improved allograft survival in B7-H4-treated recipients may
be due to the well-controlled alloreactive T-cell proliferation
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Figure 3: The mechanism of B7-H4 action in islet transplantation.
Interaction between B7-H4 and an unknown receptor on activated
T cells leads to a series of intracellular signalling cascades that result
in improved allograft survival. B7-H4 protects allograft rejection
through deletional and nondeletional mechanisms. It can limit
cytotoxic CD8+ proliferation and transcription of granzyme B. It
also reduces the Th1 response which may facilitate generation of
suppressive Foxp3+ Tregs. The combination of controlling activated
T-cell proliferation and promoting regulatory T-cell subsets results
in enhanced allograft survival and induction of donor-speciﬁc
tolerance.
suppressed by increased number of Foxp3+. Reduced IFN-
γ in the early stage may facilitate the conversion of Foxp3+
from eﬀector or na¨ ıve T cells in the late stage.
B7-H4 enhances islet allograft survival and induces
donor-speciﬁc tolerance through deletional and non-dele-
tional mechanisms (Figure 3). However, the mechanism for
tolerance induction and maintenance is not fully under-
stood. A similar number of Tregs in the periphery of failed
and surviving recipients treated with B7-H4 after second-
set transplants demonstrated that factors other than Tregs
may contribute to tolerance maintenance, such as ineﬃ-
cient inhibition of memory T cells generated in second-set
transplants [47]. Theoretically, iTregs are supposed to be
donor-speciﬁc because they are converted from eﬀector
cells that share a similar TCR repertoire. Therefore, the
generation of iTregs might result in donor-speciﬁc tolerance.
Epigenetic studies reveal that CpG dinucleotides at the
F o x p 3l o c u sa r em e t h y l a t e di nn a ¨ ıve CD4+CD25−,a c t i v a t e d
CD4+ T cells, and TGF-β-induced iTregs but completely
demethylated in nTregs, demonstrating closely compact nu-
cleosomes in the formal subsets that prevent transcription
[49]. In fact, iTregs are particularly unstable and tend to lose
Foxp3 expression more easily than nTregs. In B7-H4-treated
recipients, suppressive Tregs and cytopathogenic Teﬀsc a n
be reprogrammed upon secondary donor-speciﬁc antigen
stimulation, indicating that Tregs are involved in tolerance
induction but play a minimal role in tolerance maintenance.
The relative contributions of nTregs and iTregs in terms of6 Journal of Transplantation
synergism in promoting tolerance or redundant remain to
be elucidated.
7.B7-H4 andAutoimmunity
Mice treated with B7-H4-neutralizing mAb that blocks
endogenousB7-H4expressiondevelopacceleratedandmuch
more robust EAE, demonstrating that B7-H4 downregulates
autoimmune EAE [36]. Moreover, regulation of myelin
oligodendrocyte glycoprotein- (MOG-) induced EAE by B7-
H4-blocking mAb is associated with increased CD4+,C D 8 +,
and CD11b+ macrophages, suggesting its role in modulating
the interaction between T cells and APCs in EAE [36].
Our unpublished data show that early treatment of NOD
mice with B7-H4.Ig fusion protein signiﬁcantly reduces the
incidence of spontaneous autoimmune disease to 28.6%,
compared to 67.8% in controls, suggesting its eﬃcacy in
preventing the destruction of insulin-producing β cells by
autoreactive T cells. These promising data demonstrate B7-
H4’s potential role in inhibiting recurrence of autoimmune
diabetes in islet transplantation.
8. FutureDirections andConclusions
Much progress has been made in improving allograft
survival and induction of tolerance using costimulation
blockade. CTLA-4.Ig prolongs survival of allograft and
xenografts in various rodent models [50–52]. Its mutant
form LEA29A (belatacept), which increases the eﬃcacy of
inhibition through enhanced binding capacity and decreased
dissociation rate with B7.1/B7.2, shows promising results in
nonhuman primates and in human renal transplantation
and is currently in phase III clinical trials [53, 54]. Pro-
grammed cell death ligand 1 (PD-L1) fusion protein, PD-
L1.Ig, prolongs cardiac allograft survival in CD28-deﬁcient
but not in wild-type recipients, suggesting that PD-1:PD-
L1 and CD28/CTLA-4:B7 may be two distinct pathways
in alloimmunity [55]. Combination of PDL1.Ig and anti-
CD154 prolongs islet allograft survival [56].
In a mouse solid organ (heart) transplantation model,
B7-H4 plays a nonredundant regulatory role and functions
dominantly in the absence of CD28/CTLA-4:B7 signals,
suggesting its synergistic eﬀects with CTLA-4 to control
allograft rejection, especially facilitatory to tolerance induc-
tion [57]. In order to design new strategies for preventing
both alloreactive and autoreactive immune responses and
generating donor-speciﬁc tolerance, it will be important
to identify the detailed mechanisms in each cosignalling
pathway.
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